Stockscreener 앱 받기
5.40
2.17%
-0.12
시간 외 거래:
5.40
Cns Pharmaceuticals Inc 주식(CNSP)의 최신 뉴스
Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com
Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan
CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo
CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView
CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com
CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView
CNS Pharmaceuticals Expects to In-License or Acquire Assets by Year-End 2026 - Stock Titan
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Supernus & Indivior to merge in $2.2 billion CNS pharma deal - Voice of Healthcare
CNS Pharmaceuticals Inc (CNSP) Cash Flow - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.230|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.070|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Institutional Confidence - TradingKey
CNS Pharmaceuticals Inc (CNSP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CNS Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CNSP - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 37% Potential Upside in CNS Therapeutics - DirectorsTalk Interviews
CNS Pharmaceuticals Inc (CNSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNSP Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesEarnings Surprise Report - dars.gov.et
CNS Pharmaceuticals(CNSP) Stock Options Chain | Quotes & News - Moomoo
CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Costs PersistShare Repurchase Impact - DonanımHaber
CNS Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical Milestones - dars.gov.et
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment - TipRanks
CNS Pharmaceuticals posts investor presentation; details $22.5M financing and strategic pivot - TradingView
Strategic pivot at CNS Pharmaceuticals (NASDAQ: CNSP) backed by $22.5M PIPE - Stock Titan
CNS Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
CNS Pharmaceuticals Surges 18% as Momentum Builds (CNSP)Sweep Order Flow - dars.gov.et
CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue Stage Pressures - dars.gov.et
Price to earnings forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Enterprise value to EBIT forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNS Pharmaceuticals (CNSP) Dips 4% as Shares Approach Key Support LevelTPO Profile - dars.gov.et
Enterprise value to EBITDA forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to sales forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to book forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNS Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CNSP) - TradingView
BE50 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNSP Forecast — Price Target — Prediction for 2027 - TradingView
CNS Pharmaceuticals (CNSP) Slides 4.7% as Biotech Sentiment Wavers; Support at $3.84 in FocusSwing Entry Signals - dars.gov.et
SK Biopharm taps Insilico in $2.5B AI CNS drug discovery deal - BioWorld News
ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics - PR Newswire
CNS Pharmaceuticals (CNSP) Edges Higher as Price Approaches Key ResistanceMid Cap Momentum - dars.gov.et
Why did CNSP stock surge 330% today? - MSN
CNS Pharmaceuticals Inc (CNSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CNS Pharmaceuticals Inc (CNSP) Stock Price, Quote, News & History - Benzinga
CNS Pharmaceuticals Inc. (CNSP) Edges Higher Amid Cautious Market SentimentBuy Signal Reports - dars.gov.et
CNSP Q1 2026 Earnings: Wider Than Expected Loss, No Revenue Reported; Stock Rises 3.6%Estimate Revision Count - newsline.com
CNS Pharmaceuticals (CNSP) Tests Key Levels After Modest GainBreadth Thrust - newsline.com
1.80%
1.77%
자본화:
|
볼륨(24시간):